Emerging evidence suggests that besides the dysregulation of NK cell activation and tumor cell recognition involving NK cell receptors, alternative strategies can be exerted by the tumor to impair NK cell antitumoral functions. The gene discussed is KLRD1; the disease is neoplasm.